

# Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism

NCT07245927

---

**Status** RECRUITING  
**Sponsor** Supergene, LLC  
**Enrollment** 20,000 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Men and women aged 18 years and older.
- Verified diagnosis of massive pulmonary embolism (using computer tomography)
- Signs of overload / dysfunction of the right ventricle (at least one) in combination with persistent arterial hypotension or shock
- The time from the symptoms onset is no more than 14 days.
- Thrombolysis with the non-immunogenic staphylokinase, 15 mg as a single intravenous bolus.

### Exclusion (19)

- Increased risk of bleeding;
- extensive bleeding at present or within the previous 6 months;
- intracranial (including subarachnoid) hemorrhage at present or in history;
- hemorrhagic stroke within the last 6 months;
- a history of diseases of the central nervous system (including neoplasms, aneurysms);
- ... and 14 more (see full listing online)

## Locations (1 total)

---

E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russia